{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T06:42:52Z","timestamp":1777444972189,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2004,2,2]],"date-time":"2004-02-02T00:00:00Z","timestamp":1075680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2004,2,2]],"date-time":"2004-02-02T00:00:00Z","timestamp":1075680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2004,4,1]]},"DOI":"10.1038\/sj.bmt.1704435","type":"journal-article","created":{"date-parts":[[2004,2,2]],"date-time":"2004-02-02T16:47:58Z","timestamp":1075740478000},"page":"833-837","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Low-dose alemtuzumab (Campath\u00ae) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics"],"prefix":"10.1038","volume":"33","author":[{"given":"I F","family":"Khouri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Albitar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R M","family":"Saliba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Ippoliti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y C","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M J","family":"Keating","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R E","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,2,2]]},"reference":[{"key":"BF1704435_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0145-2126(97)00158-6","volume":"22","author":"L Ginaldi","year":"1998","unstructured":"Ginaldi L, De Martinis M, Matutes E et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998; 22: 185\u2013191.","journal-title":"Leuk Res"},{"key":"BF1704435_CR2","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1182\/blood.V82.3.807.807","volume":"82","author":"MH Gilleece","year":"1993","unstructured":"Gilleece MH, Dexter TM . Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 1993; 82: 807\u2013812.","journal-title":"Blood"},{"key":"BF1704435_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/146532401753174098","volume":"3","author":"G Hale","year":"2001","unstructured":"Hale G . The CD52 antigen and development of the Campath antibodies. Cytotherapy 2001; 3: 137\u2013143.","journal-title":"Cytotherapy"},{"key":"BF1704435_CR4","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","volume":"99","author":"MJ Keating","year":"2002","unstructured":"Keating MJ, Flinn I, Jain V et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554\u20133561.","journal-title":"Blood"},{"key":"BF1704435_CR5","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1200\/JCO.1997.15.4.1567","volume":"15","author":"A Osterborg","year":"1997","unstructured":"Osterborg A, Dyer MJ, Bunjes D et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997; 15: 1567\u20131574.","journal-title":"J Clin Oncol"},{"key":"BF1704435_CR6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1046\/j.1365-2141.1996.450989.x","volume":"93","author":"A Osterborg","year":"1996","unstructured":"Osterborg A, Fassas AS, Anagnostopoulos A et al. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 1996; 93: 151\u2013153.","journal-title":"Br J Haematol"},{"key":"BF1704435_CR7","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1182\/blood-2002-01-0159","volume":"100","author":"J Lundin","year":"2002","unstructured":"Lundin J, Kimby E, Bjorkholm M et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia. Blood 2002; 100: 768\u2013773.","journal-title":"Blood"},{"key":"BF1704435_CR8","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1200\/JCO.1997.15.7.2667","volume":"15","author":"R Pawson","year":"1997","unstructured":"Pawson R, Dyer MJ, Barge R et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 1997; 15: 2667\u20132672.","journal-title":"J Clin Oncol"},{"key":"BF1704435_CR9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1200\/JCO.2002.20.1.205","volume":"20","author":"MJ Keating","year":"2002","unstructured":"Keating MJ, Cazin B, Coutre S et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 2002; 20: 205\u2013213.","journal-title":"J Clin Oncol"},{"key":"BF1704435_CR10","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1182\/blood.V98.6.1721","volume":"98","author":"C Dearden","year":"2001","unstructured":"Dearden C, Matutes E, Cazin B et al. High remission rate in T-cell prolymphocytic leukemia with Campath-1H. Blood 2001; 98: 1721\u20131726.","journal-title":"Blood"},{"key":"BF1704435_CR11","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3109\/10428199009053522","volume":"2","author":"MSJ Dyer","year":"1990","unstructured":"Dyer MSJ, Hale G, Marcus R Waldmann H . Remission induction in patients with lymphoid malignancies using unconjugated Campath-1H monoclonal antibodies. Leuk Lymphoma 1990; 2: 179\u2013193.","journal-title":"Leuk Lymphoma"},{"key":"BF1704435_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/sj.bmt.1702477","volume":"26","author":"G Hale","year":"2000","unstructured":"Hale G, Jacobs P, Wood L et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant 2000; 26: 69\u201376.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704435_CR13","first-page":"305","volume":"17","author":"G Hale","year":"1996","unstructured":"Hale G, Waldmann H . Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection. Bone Marrow Transplant 1996; 17: 305\u2013308.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704435_CR14","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1097\/00007890-198804000-00018","volume":"45","author":"G Hale","year":"1988","unstructured":"Hale G, Cobbold S, Waldmann H . T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation. Transplantation 1988; 45: 753\u2013759.","journal-title":"Transplantation"},{"key":"BF1704435_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/sj.bmt.1701296","volume":"22","author":"E Clarke","year":"1998","unstructured":"Clarke E, Potter MN, Hale G et al. Double T cell depletion of bone marrow using sequential positive and negative cell immunoaffinity or CD34+ cell selection followed by Campath-1M; effect on CD34+ cells and progenitor cell recoveries. Bone Marrow Transplant 1998; 22: 117\u2013124.","journal-title":"Bone Marrow Transplant"},{"key":"BF1704435_CR16","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1182\/blood-2002-03-0701","volume":"100","author":"JA Perez-Simon","year":"2002","unstructured":"Perez-Simon JA, Kottaridis PD, Martino R et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002; 100: 3121\u20133127.","journal-title":"Blood"},{"key":"BF1704435_CR17","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1182\/blood.V99.3.1071","volume":"99","author":"R Chakraverty","year":"2002","unstructured":"Chakraverty R, Peggs K, Chopra R et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002; 99: 1071\u20131078.","journal-title":"Blood"},{"key":"BF1704435_CR18","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1046\/j.1365-2141.2000.01879.x","volume":"108","author":"GM Cull","year":"2000","unstructured":"Cull GM, Haynes AP, Byrne JL et al. Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity. Br J Haematol 2000; 108: 754\u2013760.","journal-title":"Br J Haematol"},{"key":"BF1704435_CR19","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1182\/blood.V96.7.2419","volume":"96","author":"PD Kottaridis","year":"2000","unstructured":"Kottaridis PD, Milligan DW, Chopra R et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96: 2419\u20132425.","journal-title":"Blood"},{"key":"BF1704435_CR20","first-page":"360b","volume":"100","author":"T Manshouri","year":"2002","unstructured":"Manshouri T, Keating M, Giles FS et al. Measuring Campath-1H: validation of a sensitive and simple enzyme-linked immunosorbent assay. Blood 2002; 100: 360b.","journal-title":"Blood"},{"key":"BF1704435_CR21","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1182\/blood-2002-09-2687","volume":"102","author":"EC Morris","year":"2003","unstructured":"Morris EC, Rebello P, Thomson KJ et al. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantation: relevance for early adoptive immunotherapy and infectious complication. Blood 2003; 102: 404\u2013406.","journal-title":"Blood"},{"key":"BF1704435_CR22","first-page":"40a","volume":"100","author":"E Morris","year":"2002","unstructured":"Morris E, Thomson K, Craddock C et al. Long-term follow-up of an alemtuzumab (Campath-1h) containing reduced intensity allogeneic transplant regimen for non-Hodgkin's lymphoma (NHL). Blood 2002; 100: 40a.","journal-title":"Blood"},{"key":"BF1704435_CR23","first-page":"354b","volume":"10","author":"D Przepiorka","year":"1998","unstructured":"Przepiorka D, Cortes J, Folloder J et al. Allogeneic transplantation for adult lymphocytic leukemia. Blood 1998; 10: 354b.","journal-title":"Blood"},{"key":"BF1704435_CR24","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1182\/blood.V99.7.2586","volume":"99","author":"P Klangsinsirikul","year":"2002","unstructured":"Klangsinsirikul P, Carter GI, Byrne JL et al. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood 2002; 99: 2586\u20132591.","journal-title":"Blood"},{"key":"BF1704435_CR25","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1182\/blood-2002-04-1093","volume":"101","author":"G Ratzinger","year":"2003","unstructured":"Ratzinger G, Reagan JL, Heller G et al. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft\u2013host interactions in transplantation. Blood 2003; 101: 1422\u20131429.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1704435","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1704435.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1704435.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T23:11:17Z","timestamp":1648077077000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1704435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2,2]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2004,4,1]]}},"alternative-id":["BF1704435"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1704435","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,2,2]]},"assertion":[{"value":"27 August 2003","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2003","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2004","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}